Maternal haemolysis, elevated liver enzymes and low platelets syndrome: Perinatal and neurodevelopmental neonatal outcomes for infants weighing less than 1250 g

Journal of Paediatrics and Child Health

Volumn 40, Issue 3, 2004, Pages 121-126

  Singhal, N ^a,c   Amin, H J ^a   Pollard, J K ^a   Tough, S C ^a   Johnston, D W ^b   Clark, D J ^a   Sauve, R ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b Decision Support Research Team   (Canada)

^c FOOTHILLS HOSPITAL   (Canada)

Author keywords

HELLP syndrome; Neonatal outcome; Neurodevelopmental outcome; Perinatal outcome

Indexed keywords

BODY WEIGHT; CEREBRAL PALSY; COGNITION; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HELLP SYNDROME; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MORBIDITY; MORTALITY; NERVE CELL DIFFERENTIATION; OUTCOMES RESEARCH; PERINATAL PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT;

CASE-CONTROL STUDIES; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HELLP SYNDROME; HUMANS; INFANT; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; MALE; NERVOUS SYSTEM DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 1842558529     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2004.00311.x     Document Type: Review

References (35)

1. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am. J. Obstet. Gynecol. 1982; 142: 159-67.
2. Brazy JE, Grimm JK, Little VA. Neonatal manifestations of severe maternal hypertension occurring before the 36th weeks of pregnancy. J. Pediatr. 1982; 100: 265-71.
3. MacKenna J, Dover NL, Brame RG. Preeclampsia associated with hemolysis, elevated liver enzymes, and low platelets - An obstetrical emergency? Obstet. Gynecol. 1983; 62: 751-4.
4. Rath W, Loos W, Kuhn W, Graeff H. Die Beduetung der frühzeitigen Labordiagnostik für das geburtshilfliche Vorgehen bei schweren Gestosen und HELLP syndrom. Gebertshilfe Frauenheilkd 1988; 48: 127-33.
5. Sibai BM, Taslimi MM, El-Nazer A, Amon E, Mabie BC, Ryan GM. Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes and low platelets in severe preeclampsia. Am. J. Obstet. Gynec. 1986; 155: 501-9.
6. Weinstein L. Preeclampsia/Eclampsia with hemolysis, elevated liver enzymes and thrombocytopenia. Obstet. Gynecol. 1985; 66: 657-60.
7. Nikischin W, Conradt A, Schroder H. Clinical course of premature and newborn infants of mothers with HELLP syndrome. Z-Geburtshilfe-Perinatol. 1991; 195: 16-20.
8. Eeltink CM, van Lingen RA, Aarnoudse JG, Derks JB, Okken A. Maternal hemolysis, elevated liver enzymes and low platelets syndrome: specific problems in the newborn. Eur. J. Pediatr. 1993; 152: 160-3.
9. Phelan JP. Obstetric critical care issues in prematurity. Clin. Perinatol. 1992; 19: 449-59.
10. Dötsch J, Hohmann M, Kühl PG. Neonatal morbidity and mortality associated with maternal hemolysis, elevated liver enzymes and low platelets syndrome. Euro. J. Pediatr. 1997; 156: 389-91.
11. Doron MW, Maklouf RA, Katz VL, Lawson EE, Stiles AD, Increased incidence of sepsis at birth in neutropenic infants of mothers with preeclampsia. J. Pediatr. 1994; 125: 452-8.
12. Harms K, Rath W, Herting E, Kuhn W. Maternal hemolysis, elevated liver enzymes, low platelet count, and neonatal outcome. Am. J. Perinatol. 1995; 12: 1-6.
13. Abramovici D, Friedman SA, Mercer BM, Audibert F, Kao L, Sibai BM. Neonatal outcome in severe preeclampsia at 24-36 weeks' gestation: Does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter? Am. J. Obstet. Gynecol. 1999; 180: 221-5.
14. Kandler C, Kevekordes B, Zenker M et al. Prognosis of children born to mothers with HELLP syndrome. J. Perinat. Med. 1998; 26: 486-90.
15. Gortner L, Pohlandt F, Bartmann P, Terinde R, Versmold H, Dorigo O. Short-term outcome in infants with birth weights <1750 g born to mothers with HELLP syndrome. J. Perinat. Med. 1992; 20: 25-8.
16. Friedman SA, Schiff E, Kao L, Sibai BM. Neonatal outcome after preterm delivery for preeclampsia. Am. J. Obstet. Gynecol. 1995; 172: 1785-92.
17. Amin H, Singhal N, Sauve RS. Impact of intrauterine growth restriction on neurodevelopmental and growth outcomes in very low birthweight infants. Acta Paediatr. 1997; 87: 306-14.
18. Levine MS. Cerebral palsy diagnoses in children over age 1 year: Standard Criteria. Arch. Phys. Med. Rehabil. 1980; 61: 385-9.
19. Bayley N. Manual for the Bayley Scales of Infant Development. New York, USA: Psychological Corporation, 1969.
20. Terman LM, Merrill MA. Stanford-Binet Intelligence Scale (Form L-M). Manual for the third revision, 1972 Norms edition. Boston, USA. Houghton Mifflin, 1973.
21. Magann EF, Perry KG, Chauhan SP, Graves GR, Blake PG, Martin JN Jr. Neonatal salvage by weeks' gestation in pregnancies complicated by HELLP syndrome. J. Soc. Gynecol. Invest. 1994; 1: 206-9.
22. van de Bor M, Verloove-Vanhorick SP, Brand R et al. Incidence and prediction of periventricular-intraventricular hemorrhage in very preterm infants. J. Perinatal Med. 1987; 15: 333-9.
23. Kuban KC, Leviton A, Pagano M, Fenton T, Strassfeld R, Wolff M. Maternal toxemia is associated with reduced incidence of germinal matrix hemorrhage in premature babies. J. Child Neurol. 1992; 7: 70-6.
24. O'Shea M, Savitz DA, Hage ML, Feinstein KA. Prenatal events and the risk of subependymal/intraventricular haemorrhage in very low birthweight neonates. Paediatr. Perinat. Epidemiol. 1992; 6: 352-62.
25. Gray PH, O'Callaghan MJ, Mohay HA, Burns YR, King JF. Maternal hypertension and neurodevelopmental outcome in very preterm infants. Arch. Dis. Child Fetal Neonatal Ed. 1998; 79: F88-F93.
26. Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995; 95: 263-9.
27. Hauth JC, Goldenberg RL, Nelson KG, DuBard MB, Pertala MA, Gaudier FL. Reduction of cerebral palsy with maternal MgSO4 treatment in newborns weighing 500-1000 g. Am. J Obstst Gynecol. 1995; 172: 419.
28. Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3-5 years. JAMA 1996; 276: 1805-10.
29. Hoffman DJ, Marro PJ, McGowan JE, Mishra OP, Delivoria-Papadopoulos M. Protective effect of Mg infusion on NMDA receptor binding characteristics during cerebral cortical hypoxia in the newborn piglet. Brain Res. 1994; 644: 144-9.
30. Marrat S, Gressens P, Gadisseux J-F, Evrard P. Prevention by magnesium of excitotoxic neuronal death in the developing brain: an animal model for clinical intervention studies. Dev. Med. Child Neurol. 1995; 37: 473-84.
31. McDonald JW, Silverstein FS, Johnston MV. Magnesium reduces N-methyl-D-aspartate (NMDA)-mediated brain injury in perinatal rats. Neurosci. Lett. 1990; 109: 234-8.
32. Kass EH. Magnesium and the pathogenesis of toxic shock syndrome. Rev. Infect. Dis. 1989; 11 (Suppl. 1): 5167-75.
33. Garcia Vescovi E, Soncini FC, Groisman EA. Mg2+ as an extracellular signal: environmental regulation of salmonella virulence. Cell 1996; 84: 165-74.
34. Herzog WR, Serebruany VL. How magnesium therapy may influence clinical outcome in acute myocardial infarction: review of potential mechanisms. Coron. Artery Dis. 1996; 7: 364-71.
35. Mittendorf R, Dambrosia J, Pryde PG et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am. J. Obstst. Gynecol. 2002; 186: 1111-18.